zPredicta acquired by Predictive Oncology (NASDAQ:POAI)

Cell culture model for anti-cancer therapeutics
Reading Time: 2 minutes

Predictive Oncology Acquires zPREDICTA

This post was published on 3 May 2022 and updated on 20 October 2022.

 

In this chapter of our ongoing series of Portfolio Updates, we take a look at the journey of biotech company zPREDICTA from its capital raising on the Propel(x) platform to its acquisition by the publicly listed company Predictive Oncology (POAI).

zPREDICTA is an innovative biotech company focused on applying Artificial Intelligence (AI) to develop personalized cancer therapies to deliver effective treatments and improve patient outcomes. The company is a leader in the field of tumor-specific 3D cancer cell models for in vitro testing of anti-cancer therapeutics. Their cell culture models are specific to the disease and the target tissue, which can improve predictive analytics.

In 2016, Propel(x) investors participated in a Seed Round capital raise utilizing a Convertible Note structure. 

After ongoing success developing their innovative technology, zPREDICTA caught the attention of publicly listed company Predictive Oncology. Fast forward to the end of 2021, and that interest culminated in the acquisition of zPREDICTA by Predictive Oncology. You can read more about the acquisition in the press release headlined The Value That zPREDICTA Brings to Predictive Oncology.

Propel(x) seed investors shared in a liquidity event when the acquisition was completed for an undisclosed sum.

If you are interested in building your portfolio by adding investments in startups, you can find more information here on how to start angel investing and how to find opportunities for angel investing on the Propel(x) platform.

 

This article is for informational purposes only.  We do not provide legal, financial, or tax advice and investors should consult their advisors prior to making any investment. As with any investment, past performance is no guarantee of future performance, and any investment decision must balance the risk against the potential return.

Private investments are highly illiquid and risky and are not suitable for all investors.  There is no guarantee that a liquidity event will ever take place.Even if a liquidity event takes place there is no guarantee that the investor will earn a return. Private placements are high-risk and there is a risk that an investor could lose their entire investment. 

This article contains links to third-party websites. These links are provided solely as a convenience to you and do not imply an affiliation, sponsorship, endorsement, approval, investigation, verification, or monitoring by us of the contents on such third-party websites. We are not responsible for the content of any website owned by a third party and do not guarantee the accuracy, timeliness, completeness, suitability, reliability, or usefulness of any information.

All securities offerings are done through Propel(x)’s affiliated broker-dealer, Hubble Investments.

Twitter
LinkedIn
Facebook

Start Investing Today​